Patients were matched on therapy class, age, gender, payer type, geography, and if new to therapy • Look-back and Follow-up: a 12-month look back period from index was used to determine if patients were "New to Therapy" or "Continuing"; a 6-month follow-up period from the index date was used to measure study outcomes • Outcomes: Persistence was calculated at the Hypertension/Lipid market level during 6 months post-index period; and was measured using a 10-day refill gap past the end of the days' supply of the previous prescription. Differences were tested using Chi-square
• Poor adherence to medication in chronic diseases is recognized as a serious public health problem by the United States (US) Center for Disease Control. Apart from leading to poor treatment outcomes, non-adherence is estimated to contribute $100 to $300 billion in avoidable healthcare cost in the US annually. 1-4 • Medication adherence is crucial to better treatment efficacy, healthcare cost containment, and in some cases, for preventing resistance to therapy. 5-6 • With the exponential growth in mobile health technologies, using smartphone applications (apps) to improve medication adherence is a novel approach which can have long term benefits for patients, providers and payers. 1, 7, 8 Methods • There were a total of 406 Anti Hypertension (AH) and 150 Cholesterol Lowering (CL) users matched to controls • The mean (SD) age of the patients was 52.5 (12.0) and 54.6 (10.7) years for AH and CL, respectively • The study groups were approximately equal in male-female ratio • Of AH patients, 7.9% were new to therapy, while 7.3% CL patients were new to therapy • Comparing all patients at 6 months, a 5.4% higher persistence for AH (69.7% vs. 64.3%, p=0.05), and a 10.7% higher persistence for CL (65.3% vs. 54.7%, p=0.03) was observed for app users -AH app users exhibited higher persistency at all reporting periods (Figure 1 ) -CL app users exhibited higher persistency by the 6 th reporting period (Figure 2 ) -The relative increase in persistence was 8.4% at 6 month for AH app users group and it was 19.5% for the CL app users at the same time period • Similar results were observed among continuing patients at 6 months, with AH app users having a 4.5% higher persistence (71.7% vs. 67.1%, p=0.09) (Figure 3) Results Continued
